Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Featured News Pfizer Adds to Its Big Bet on Weight Loss DrugsWritten by Jordan Chussler. Published 12/16/2025. 
Key Points - The health care sector has led the S&P 500 over the three months, but Pfizer has lagged of late, slipping 5% since the start of October.
- As the Big Pharma company continues to struggle to replace COVID-19 vaccine revenue, it is heavily learning into the semaglutide and GLP-1 weight loss drug trend.
- Last week, the company signed a $2.1 billion licensing agreement with a Chinese pharma company to develop its early-stage weight loss pill.
Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included all of the Big Pharma mainstays. Pfizer (NYSE: PFE), the maker of Chantix, Eliquis and Paxlovid, has seen its shares slide 5% since the start of October. By comparison, other mega-cap pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), Regeneron Pharmaceuticals (NASDAQ: REGN), and Eli Lilly (NYSE: LLY) are up nearly 14%, 24%, and 25%, respectively, over the same time frame. A major force in the crypto world is quietly becoming one of gold's most aggressive buyers — and most investors have no idea it's happening.
A longtime gold analyst says profits from a leading stablecoin operation are being funneled into physical gold at a scale that could materially impact supply and demand. After a recent meeting with insiders, he began outlining what this trend could mean for gold prices and a small group of companies positioned to benefit. Read the full gold briefing here And despite Pfizer making headlines on Nov. 13 after acquiring obesity biotech Metsera in a $10 billion deal, the stock has only mustered a 0.23% gain since then. The nearly 177‑year‑old biopharma company is once again looking to expand its role in the weight‑loss drug market, with management and shareholders hoping that doing so can help recover revenue lost as demand for mRNA COVID‑19 vaccines has waned. Pfizer Looks to Gain Market Share After Enormous Deal With YaoPharma On Tuesday, Dec. 9, Pfizer struck a $2.1 billion licensing deal with China's YaoPharma to develop a GLP‑1 oral weight‑loss pill that is in early‑stage development. The drug is similar in mechanism to Wegovy, Novo Nordisk's game‑changing injectable GLP‑1 therapy. News of a yet‑to‑be‑approved pill may not move the stock in the short term, but it does reflect the company's commitment and momentum in the obesity treatment market. The agreement calls for Pfizer to pay a $150 million upfront fee to YaoPharma's parent, Shanghai Fosun Pharmaceutical, which has an $8.4 billion market cap. Pfizer could also pay YaoPharma up to $1.94 billion in milestone payments tied to regulatory and development progress, along with royalties on sales if the drug reaches the market. Those milestone payments will be contingent on YaoPharma successfully advancing the weight‑loss pill through Phase 1 trials, after which Pfizer will take control of later‑stage development. Pfizer also plans to conduct combination studies—currently in mid‑stage development—combining YaoPharma's pill with Pfizer's GIP‑targeting compound. That approach mirrors Eli Lilly's strategy with Zepbound and Mounjaro, which target both GLP‑1 and GIP pathways. Pfizer Is Positioning Itself for the Future of the Weight‑Loss Drug Market The deal underscores how aggressively Pfizer's executives are pursuing a long‑term position in the GLP‑1 and broader obesity treatment market. Pfizer's leadership has demonstrated a willingness to invest roughly $10.1 billion over the past month as it targets a rapidly expanding industry. Forecasts from market analysis firm Grand View Research suggest the GLP‑1 weight‑loss drug market will grow at a compound annual growth rate (CAGR) of 18.54% from 2025 to 2030, climbing from under $14 billion at the start of the year to an estimated $48.84 billion by 2030. Grand View Research found that North America accounts for the largest revenue share—more than 75% of the GLP‑1 agonists market. While alternatives such as lifestyle changes and bariatric surgery exist, GLP‑1 drugs remain the preferred option among many physicians and patients. Patient Investors Can Enjoy PFE's Sizable Dividend Shareholders are hoping Pfizer's push into the weight‑loss drug market pays off after the stock has delivered a loss of more than 31% over the past five years. Much of that decline stems from falling COVID‑vaccine sales, which caused revenue growth to swing from more than 95% at the end of 2021 to a decline exceeding 41% by the end of 2023. Last year Pfizer rebounded modestly, registering a nearly 7% increase in revenue. Meanwhile, the stock's dividend has eased some investor concerns. Pfizer remains a strong dividend payer with a current yield of 6.65%—about $1.72 per share annually. The company has raised its payout for 16 consecutive years, making the stock attractive to income investors despite a high payout ratio. For investors willing to forego immediate capital gains and who are bullish on the near‑ to mid‑term prospects for prescription weight‑loss drugs, Pfizer can continue to provide income while serving as a speculative way to play the GLP‑1 market. However, growth‑focused investors might not tolerate another year of underperformance. Analysts' average 12‑month price target implies roughly 10% potential upside from the current price and corresponds with a consensus Hold rating. Meanwhile, short interest has been rising as the stock attracts Wall Street skeptics. Currently, about $3.58 billion of the float is shorted—nearly 84% higher than PFE's short position at the end of January 2025.
| 
